121 related articles for article (PubMed ID: 8380487)
1. Milacemide therapy for Parkinson's disease.
Giuffra ME; Sethy VH; Davis TL; Mouradian MM; Chase TN
Mov Disord; 1993; 8(1):47-50. PubMed ID: 8380487
[TBL] [Abstract][Full Text] [Related]
2. A trial of dextromethorphan in parkinsonian patients with motor response complications.
Verhagen Metman L; Blanchet PJ; van den Munckhof P; Del Dotto P; Natté R; Chase TN
Mov Disord; 1998 May; 13(3):414-7. PubMed ID: 9613730
[TBL] [Abstract][Full Text] [Related]
3. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease and milacemide.
Youdim MB
Mov Disord; 1994 Sep; 9(5):585-6. PubMed ID: 7990857
[No Abstract] [Full Text] [Related]
5. Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Bara-Jimenez W; Dimitrova T; Sherzai A; Favit A; Mouradian MM; Chase TN
Mov Disord; 2004 Oct; 19(10):1183-6. PubMed ID: 15390018
[TBL] [Abstract][Full Text] [Related]
6. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
Wolters EC; Horstink MW; Roos RA; Jansen EN
Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
[No Abstract] [Full Text] [Related]
7. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
Vitek JL; Bakay RA; Freeman A; Evatt M; Green J; McDonald W; Haber M; Barnhart H; Wahlay N; Triche S; Mewes K; Chockkan V; Zhang JY; DeLong MR
Ann Neurol; 2003 May; 53(5):558-69. PubMed ID: 12730989
[TBL] [Abstract][Full Text] [Related]
9. Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial.
Grundmann M; Schimrigk K
J Neural Transm Suppl; 1987; 25():115-9. PubMed ID: 3323420
[TBL] [Abstract][Full Text] [Related]
10. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
Metman LV; Sethy VH; Roberts JR; Bravi D; Hoff JI; Mouradian MM; Chase TN
Mov Disord; 1994 Sep; 9(5):577-81. PubMed ID: 7990854
[TBL] [Abstract][Full Text] [Related]
11. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
Bravi D; Davis TL; Mouradian MM; Chase TN
Mov Disord; 1993 Apr; 8(2):195-7. PubMed ID: 8097280
[TBL] [Abstract][Full Text] [Related]
13. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
14. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A
Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211
[TBL] [Abstract][Full Text] [Related]
16. A double-blind evaluation of ciladopa in Parkinson's disease.
Weiner WJ; Factor SA; Sanchez-Ramos J; Berger J
Mov Disord; 1987; 2(3):211-7. PubMed ID: 3332914
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
[TBL] [Abstract][Full Text] [Related]
18. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
[TBL] [Abstract][Full Text] [Related]
19. Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
Addy C; Assaid C; Hreniuk D; Stroh M; Xu Y; Herring WJ; Ellenbogen A; Jinnah HA; Kirby L; Leibowitz MT; Stewart RM; Tarsy D; Tetrud J; Stoch SA; Gottesdiener K; Wagner J
J Clin Pharmacol; 2009 Jul; 49(7):856-64. PubMed ID: 19491335
[TBL] [Abstract][Full Text] [Related]
20. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
